TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Early Unfavorable Classic HL
Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Patients are designated as having early unfavorable classic Hodgkin lymphoma (HL) when they have clinical stage I or stage II disease and one or more of the following risk factors:
B symptoms (unexplained fever ≥38°C, soaking night sweats, unexplained weight loss ≥10% within 6 months).
Extranodal disease.
Bulky disease (≥10 cm or >33% of the chest diameter on chest x-ray).
Three or more sites of nodal involvement.
Sedimentation rate of 50 mm/h or higher.
A retrospective review found that infradiaphragmatic early-stage disease appears to have an inferior outcome compared with the more frequent (>90%) supradiaphragmatic disease, with a decrement in overall survival (OS) rates of 6% (91.5% vs. 97.6%; P < .001).[1][Level of evidence C2]
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice